The FDA Just Admitted Chemo Causes Cancer—So Why Are We Still Paying for Poison?
You think you’re fighting a disease. You sit in that sterile room, watching the clear liquid drip into your veins, trusting the white coats who tell you this is the only way. You sell your house, drain your 401(k), and let them pump you full of toxins that make you vomit until your ribs ache. And what do they tell you? “It’s worth it. It’s the gold standard.”
But what if the gold standard is actually a gilded cage? What if the cure is the new disease?
I’m not talking about some fringe blog post from a guy in his mom’s basement. I’m talking about the National Cancer Institute’s own fact sheet, buried on their website like a classified file, which openly states that the very chemotherapy drugs used to treat cancer—drugs like cyclophosphamide and melphalan—are themselves *carcinogenic*. They can cause secondary cancers. Leukemia, specifically. A brand-new, often deadlier cancer, born from the ashes of the first one.
Wake up, people. The FDA has known this for decades. The American Cancer Society has known this. They’ve known it since the 1970s, when the data first started rolling in from Vietnam veterans exposed to Agent Orange, which contains the same class of chemicals. But did they stop the gravy train? No. They built a multi-billion-dollar industry on a paradox: treating fire with gasoline.
Let’s connect the dots that the mainstream media refuses to touch.
First, the economics. Chemotherapy is a massive cash cow. The global cancer drug market is projected to hit over $250 billion by 2030. That’s not a typo. Every infusion is a billable event. Every “preventative” chemo session for a patient who just had a tumor removed is another Mercedes in the doctor’s parking lot. Do you honestly think they’re going to stop that flow because of a little thing like “evidence”? Remember, Big Pharma doesn’t want to cure cancer. They want to *treat* it. A cured patient is a lost customer. A patient with a chronic, recurring, treatment-resistant cancer is a lifetime annuity.
Second, the science they don’t want you to read. Studies published in the *Journal of Clinical Oncology* have shown that the risk of developing therapy-related myeloid neoplasms (t-MN)—that’s the fancy term for chemo-caused leukemia—is significantly elevated in patients who receive certain alkylating agents. We’re not talking about a 0.001% chance. We’re talking about a real, measurable risk that can be as high as 5-10% within a decade for some regimens. Now, look at the woman in the pink ribbon t-shirt who just got diagnosed with stage 0 breast cancer—the one they rushed into radiation and chemo for a “precaution.” Did anyone tell her that the “precaution” might give her a blood cancer that has a median survival of less than a year? No. They handed her a pamphlet and a bill.
Third, the alternative story. Why are we not hearing about the metabolic approaches? The research into fasting-mimicking diets that make cancer cells vulnerable? The work on repurposing cheap, off-patent drugs like metformin, which has shown incredible promise in starving cancer cells of their glucose fuel? Why is the FDA fast-tracking a $10,000-a-month biologic that extends life by three months, but blocking clinical trials for a $0.50-a-day protocol that shows tumor regression in animal models? Follow the money. It always leads to the same boardrooms.
This isn’t a conspiracy theory; it’s a business model. The American healthcare system is not designed for health. It’s designed for throughput. The fact that the FDA’s own black box warnings—the strongest warning they can issue—appear on these drugs, admitting they cause secondary malignancies, is the smoking gun. It’s printed right there on the insert you probably threw away.
But here’s the kicker. The “standard of care” is legally protected. If a doctor suggests a non-toxic, metabolic approach, he risks losing his license and facing malpractice suits. If he pumps you full of poison that gives you a second cancer, he’s considered a hero. It’s a perverse incentive structure that punishes the healer and rewards the salesman.
So why are we still paying for poison? Because we’re told to. Because we’re scared. Because the machine tells us that without the chemo, we’ll die. But the data tells a different story. The data shows that for some advanced solid tumors, chemotherapy has a response rate of less than 5%. That means 95% of the people enduring that hell get zero benefit. Zero. Yet the protocol remains.
We need to shift the paradigm. We need to stop treating the tumor and start treating the terrain. Why does the cancer grow? What is the body’s environment that allows it to thrive? Acidosis? Chronic inflammation? Insulin resistance? These are the questions that lead to answers. Chemo just nukes the whole landscape and hopes the seeds don’t blow back into the wind. But they do. They always do.
Don’t be naive. The next time you see a commercial for a cancer drug with a smiling woman walking through a sunflower field, remember the FDA warning. Remember the secondary leukemia. Remember that the cure is often worse than the disease, and that the disease is the profit.
It’s time to stop trusting the narrative and start asking the hard questions. Why isn’t prevention the priority? Why is the research budget 99% for toxic chemicals and 1% for lifestyle and metabolic therapy? Why are we still in the dark ages of oncology?
You are not a number. You are not a revenue stream. You are a human being with a body that has an incredible capacity to heal—if you stop poisoning it. The truth is out there, tucked away in the footnotes and the fine print. Start digging. Your life might depend on it.
Now, look at the label on that vial. It doesn’t say “cure.”
Final Thoughts
Let’s be brutally honest: despite the breathless headlines about miracle cures, the real story of cancer is one of attrition—a grinding war fought not in a single decisive battle, but through incremental advances in early detection and combination therapies. The most profound shift I’ve witnessed isn’t a magic bullet, but the quiet realization that we must treat cancer as a chronic condition to be managed, not just an acute invader to be slaughtered. If there’s a takeaway from decades of reporting, it’s that the future belongs to those who understand the tumor’s biology as intimately as we know our own immune system, not to those promising a single, silver-bullet victory.